nimesulide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
nicotinic acid or nicotinoyl alcohol derivatives 1935 51803-78-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nimesulide
  • mesulide
  • mesulid
  • nimsulid
  • sulidene
  • sulide
  • sulidan
  • Molecular weight: 308.31
  • Formula: C13H12N2O5S
  • CLOGP: 2.91
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 1
  • TPSA: 101.22
  • ALOGS: -4.23
  • ROTB: 4

Drug dosage:

DoseUnitRoute
0.20 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.01 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 2 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 9.27 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1985 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug abuse 92.25 25.96 47 2221 72471 63414283
Ductus arteriosus stenosis foetal 85.64 25.96 13 2255 172 63486582
Renal failure neonatal 85.36 25.96 13 2255 176 63486578
Neonatal respiratory acidosis 69.71 25.96 11 2257 190 63486564
Cyanosis neonatal 55.32 25.96 10 2258 399 63486355
Bradycardia neonatal 52.63 25.96 11 2257 941 63485813
Neonatal respiratory distress syndrome 50.33 25.96 13 2255 2805 63483949
Hepatocellular injury 44.47 25.96 21 2247 27360 63459394
Gastritis erosive 40.54 25.96 13 2255 6026 63480728
Maximal voluntary ventilation abnormal 37.25 25.96 5 2263 25 63486729
Atrioventricular block complete 36.56 25.96 13 2255 8238 63478516
Contraindication to medical treatment 32.72 25.96 7 2261 669 63486085
Duplicate therapy error 31.33 25.96 5 2263 93 63486661
Intentional self-injury 30.71 25.96 16 2252 25671 63461083
Tonsillar exudate 30.53 25.96 4 2264 16 63486738
Polyuria 28.76 25.96 11 2257 8531 63478223
Product dispensing issue 28.38 25.96 5 2263 172 63486582
Premature baby 27.93 25.96 14 2254 20721 63466033
Abdominal pain upper 27.05 25.96 35 2233 206409 63280345
Diabetic metabolic decompensation 26.26 25.96 7 2261 1703 63485051
Emphysema 26.13 25.96 11 2257 10927 63475827

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Polyneuropathy in malignant disease 59.75 35.75 10 1331 235 34955355
Body mass index abnormal 56.48 35.75 9 1332 154 34955436
Ligament calcification 53.79 35.75 9 1332 211 34955379
Rash maculovesicular 52.93 35.75 7 1334 28 34955562
Confabulation 50.04 35.75 8 1333 140 34955450
Lip erythema 48.49 35.75 7 1334 59 34955531
Palmoplantar pustulosis 44.03 35.75 7 1334 118 34955472
Nasal mucosal disorder 43.64 35.75 7 1334 125 34955465
Face oedema 41.97 35.75 16 1325 11500 34944090
Negativism 41.72 35.75 8 1333 411 34955179
Ankylosing spondylitis 40.60 35.75 13 1328 5591 34949999
Sacroiliitis 36.57 35.75 9 1332 1489 34954101
Allodynia 36.26 35.75 8 1333 823 34954767
Quality of life decreased 36.19 35.75 11 1330 3990 34951600
Spinal pain 35.95 35.75 12 1329 5877 34949713

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug abuse 100.27 22.85 72 3529 162619 79578168
Renal failure neonatal 84.88 22.85 12 3589 71 79740716
Ductus arteriosus stenosis foetal 83.78 22.85 12 3589 79 79740708
Neonatal respiratory acidosis 71.35 22.85 10 3591 55 79740732
Bradycardia neonatal 68.79 22.85 10 3591 74 79740713
Cyanosis neonatal 63.00 22.85 9 3592 58 79740729
Neonatal respiratory distress syndrome 57.61 22.85 10 3591 247 79740540
Polyneuropathy in malignant disease 56.48 22.85 10 3591 278 79740509
Ligament calcification 52.26 22.85 9 3592 212 79740575
Rash maculovesicular 51.20 22.85 7 3594 31 79740756
Body mass index abnormal 51.15 22.85 9 3592 241 79740546
Gastritis erosive 51.04 22.85 19 3582 10828 79729959
Intentional self-injury 41.88 22.85 23 3578 32396 79708391
Face oedema 39.23 22.85 21 3580 28115 79712672
Premature baby 39.22 22.85 12 3589 3768 79737019
Confabulation 39.03 22.85 8 3593 490 79740297
Lip erythema 37.29 22.85 7 3594 271 79740516
Maximal voluntary ventilation abnormal 35.16 22.85 5 3596 31 79740756
Nasal mucosal disorder 35.10 22.85 7 3594 373 79740414
Sacroiliitis 35.09 22.85 11 3590 3743 79737044
Negativism 34.64 22.85 8 3593 855 79739932
Hepatocellular injury 33.73 22.85 23 3578 47570 79693217
Palmoplantar pustulosis 32.12 22.85 7 3594 576 79740211
Erosive duodenitis 32.01 22.85 9 3592 2108 79738679
Foetal exposure during pregnancy 30.41 22.85 11 3590 5779 79735008
Allodynia 29.50 22.85 8 3593 1640 79739147
Enanthema 29.50 22.85 7 3594 842 79739945
Spinal pain 28.76 22.85 14 3587 15378 79725409
Tonsillar exudate 28.54 22.85 4 3597 22 79740765
Oral mucosa erosion 28.18 22.85 8 3593 1939 79738848
Genital ulceration 27.69 22.85 7 3594 1093 79739694
Mixed liver injury 27.53 22.85 11 3590 7567 79733220
Product dispensing issue 26.33 22.85 5 3596 206 79740581
Low birth weight baby 26.21 22.85 6 3595 617 79740170
Angioedema 26.16 22.85 24 3577 76011 79664776
Intestinal haemorrhage 25.70 22.85 10 3591 6416 79734371
Atrioventricular block complete 24.85 22.85 13 3588 16597 79724190
Duplicate therapy error 24.46 22.85 5 3596 302 79740485
Drug interaction 24.22 22.85 56 3545 415127 79325660
Quality of life decreased 24.16 22.85 11 3590 10409 79730378
Rash maculo-papular 23.91 22.85 20 3581 56058 79684729
Stevens-Johnson syndrome 23.27 22.85 17 3584 39149 79701638
Polyneuropathy 22.85 22.85 14 3587 24137 79716650

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC M01AX17 MUSCULO-SKELETAL SYSTEM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
Other antiinflammatory and antirheumatic agents, non-steroids
ATC M02AA26 MUSCULO-SKELETAL SYSTEM
TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
Antiinflammatory preparations, non-steroids for topical use
MeSH PA D000700 Analgesics
MeSH PA D018712 Analgesics, Non-Narcotic
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D000894 Anti-Inflammatory Agents, Non-Steroidal
MeSH PA D018501 Antirheumatic Agents
MeSH PA D016861 Cyclooxygenase Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents
CHEBI has role CHEBI:35475 non-steroidal anti-inflammatory agent
CHEBI has role CHEBI:50629 COX-2 inhibitor

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 6.03 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Prostaglandin G/H synthase 2 Enzyme IC50 5.91 WOMBAT-PK
Prostaglandin G/H synthase 1 Enzyme IC50 5.42 CHEMBL
Sodium-dependent dopamine transporter Transporter Ki 4.93 DRUG MATRIX
Aromatase Enzyme IC50 4.57 WOMBAT-PK
cAMP-specific 3',5'-cyclic phosphodiesterase 4A Enzyme IC50 5.70 WOMBAT-PK
Myeloperoxidase Enzyme IC50 5.68 CHEMBL
Interstitial collagenase Enzyme IC50 4.63 DRUG MATRIX
Prostaglandin G/H synthase 1 Enzyme IC50 5.21 CHEMBL
Prostaglandin G/H synthase 2 Enzyme IC50 6.40 CHEMBL
Sodium-dependent neutral amino acid transporter B(0)AT1 Transporter INHIBITOR IC50 4.64 IUPHAR
Dipeptidyl peptidase 3 Enzyme Ki 4.16 CHEMBL

External reference:

IDSource
D01049 KEGG_DRUG
C0132515 UMLSCUI
CHEBI:44445 CHEBI
NIM PDB_CHEM_ID
CHEMBL56367 ChEMBL_ID
DB04743 DRUGBANK_ID
C012655 MESH_SUPPLEMENTAL_RECORD_UI
4495 PUBCHEM_CID
7401 IUPHAR_LIGAND_ID
4885 INN_ID
V4TKW1454M UNII
53694 RXNORM
004182 NDDF
703479000 SNOMEDCT_US
703480002 SNOMEDCT_US

Pharmaceutical products:

None